NCT02988401View on ClinicalTrials.gov

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Interventions
DRUG

Insulin

All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.

DRUG

Placebo (Sterile diluent)

All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.

Trial Locations (1)

21287

Johns Hopkins University School of Medicine, Baltimore

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Johns Hopkins University

OTHER

NCT02988401 - Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis | Biotech Hunter | Biotech Hunter